MX2018003101A - Activo de polipeptidos de lisina contra bacterias gram-negativas. - Google Patents

Activo de polipeptidos de lisina contra bacterias gram-negativas.

Info

Publication number
MX2018003101A
MX2018003101A MX2018003101A MX2018003101A MX2018003101A MX 2018003101 A MX2018003101 A MX 2018003101A MX 2018003101 A MX2018003101 A MX 2018003101A MX 2018003101 A MX2018003101 A MX 2018003101A MX 2018003101 A MX2018003101 A MX 2018003101A
Authority
MX
Mexico
Prior art keywords
negative bacteria
lysin polypeptides
active against
against gram
gram
Prior art date
Application number
MX2018003101A
Other languages
English (en)
Inventor
Schuch Raymond
Wittekind Michael
Hoffenberg Simon
Original Assignee
Contrafect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contrafect Corp filed Critical Contrafect Corp
Publication of MX2018003101A publication Critical patent/MX2018003101A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción proporciona métodos y composiciones útiles para la mejora profiláctica y terapéutica y tratamiento de infecciones causadas por bacterias Gram-negativas, que incluyen Pseudomonas aeruginosa. La descripción proporciona además composiciones y métodos para incorporar y utilizar polipéptidos de lisina de la presente descripción para aumentar la eficacia de antibióticos generalmente adecuados para el tratamiento de la infección bacteriana Gram-negativa.
MX2018003101A 2015-09-17 2016-09-16 Activo de polipeptidos de lisina contra bacterias gram-negativas. MX2018003101A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562220212P 2015-09-17 2015-09-17
US201562247619P 2015-10-28 2015-10-28
PCT/US2016/052338 WO2017049233A2 (en) 2015-09-17 2016-09-16 Lysin polypeptides active against gram-negative bacteria

Publications (1)

Publication Number Publication Date
MX2018003101A true MX2018003101A (es) 2018-12-17

Family

ID=57121513

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2018003100A MX2018003100A (es) 2015-09-17 2016-09-16 Uso de lisina para restaurar/aumentar la actividad antibacteriana en presencia de agente tensoactivo pulmonar de antibioticos inhibidos en el mismo.
MX2018003101A MX2018003101A (es) 2015-09-17 2016-09-16 Activo de polipeptidos de lisina contra bacterias gram-negativas.
MX2022006525A MX2022006525A (es) 2015-09-17 2018-03-13 Activo de polipeptidos de lisina contra bacterias gram-negativas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018003100A MX2018003100A (es) 2015-09-17 2016-09-16 Uso de lisina para restaurar/aumentar la actividad antibacteriana en presencia de agente tensoactivo pulmonar de antibioticos inhibidos en el mismo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022006525A MX2022006525A (es) 2015-09-17 2018-03-13 Activo de polipeptidos de lisina contra bacterias gram-negativas.

Country Status (15)

Country Link
US (5) US11357833B2 (es)
EP (4) EP3349781A2 (es)
JP (3) JP2018534247A (es)
KR (2) KR20180064417A (es)
CN (3) CN116077630A (es)
AU (3) AU2016324307B2 (es)
BR (2) BR112018005318A2 (es)
CA (2) CA2998507A1 (es)
ES (1) ES2934714T3 (es)
HK (1) HK1256628A1 (es)
IL (2) IL258123B (es)
MX (3) MX2018003100A (es)
RU (2) RU2728682C2 (es)
WO (2) WO2017049233A2 (es)
ZA (2) ZA201801315B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013170022A1 (en) * 2012-05-09 2013-11-14 Contrafect Corporation Biofilm prevention, disruption and treatment with bacteriophage lysin
CA2953446A1 (en) * 2014-06-26 2015-12-30 The Rockefeller University Acinetobacter lysins
CN104805066B (zh) * 2015-05-18 2018-04-24 武汉菲吉乐科生物科技有限公司 一种葡萄球菌裂解酶及其应用
RU2728682C2 (ru) 2015-09-17 2020-07-31 Контрафект Корпорейшн Применение лизина для восстановления/увеличения антибактериальной активности антибиотиков в присутствии легочного сурфактанта, который ингибирует указанные антибиотики
BR112020011433A2 (pt) * 2017-12-12 2020-12-01 Contrafect Corporation identificação de lisinas e seus derivados com atividade bacteriana contra pseudomonas aeruginosa
WO2019126670A1 (en) 2017-12-22 2019-06-27 The Rockefeller University Recombinant pseudomonas aeruginosa lysins
EP3731843A4 (en) 2017-12-28 2021-11-17 Consegna Pharma Inc. LONG-TERM OPIOID ANTAGONISTS
US10988520B2 (en) 2018-03-29 2021-04-27 Contrafect Corporation Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
AU2019245369A1 (en) * 2018-03-29 2020-10-29 Contrafect Corporation Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
AU2019245333A1 (en) * 2018-03-29 2020-10-29 Contrafect Corporation Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria
EP3813796A4 (en) * 2018-05-23 2022-06-22 The Rockefeller University RECOMBINANT LYSINE
KR20210024005A (ko) * 2018-06-22 2021-03-04 콘트라펙트 코포레이션 스태필로코커스 아우레우스 및 그람 양성 세균을 항생제에 재민감화시키기 위한 리신 및 이의 유도체
CN110664881A (zh) * 2018-07-03 2020-01-10 上海海洋大学 抗水产致病性弗氏柠檬酸杆菌的药物及其制备方法
EP3840771A4 (en) * 2018-08-23 2023-04-19 Contrafect Corporation ANTIMICROBIAL LYSINE-PEPTIDE (AMP) POLYPEPTIDE CONSTRUCTIONS, LYSINES, ISOLATED POLYNUCLEOTIDES ENCODING THEM AND THEIR USES
US20220024992A1 (en) * 2018-11-02 2022-01-27 The Rockefeller University Compositions and methods comprising lysocins as bioengineered antimicrobials for use in targeting gram-negative bacteria
CA3134154A1 (en) * 2019-03-22 2020-10-01 Contrafect Corporation Method of treating infective endocarditis
CA3136126A1 (en) * 2019-04-05 2020-10-08 Contrafect Corporation Lysins and derivatives thereof with bactericidal activity against pseudomonas aeruginosa, in the presence of human serum
EP3996740A4 (en) * 2019-07-12 2023-07-05 Contrafect Corporation THERAPEUTIC PROTEIN FORMULATIONS INCLUDING ANTIBODIES AND THEIR USES
CN110684760A (zh) * 2019-09-27 2020-01-14 吉林大学 一种杀灭葡萄球菌的基因工程裂解酶及制备方法和应用
EP4118192A1 (en) 2020-03-11 2023-01-18 Telum Therapeutics S.L. New recombinant lysin and its use in the treatment of gram-negative bacterial infections
WO2021207679A1 (en) * 2020-04-10 2021-10-14 Liberty Biosecurity, Llc Polypeptide compositions and uses thereof
US20210324359A1 (en) * 2020-04-17 2021-10-21 Contrafect Corporation Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in treating endocarditis
KR102224897B1 (ko) * 2020-05-22 2021-03-08 주식회사 라이센텍 신규한 폴리펩타이드 및 이를 포함하는 그람음성균에 대한 항생제
KR102228999B1 (ko) * 2020-08-27 2021-03-18 주식회사 라이센텍 폴리펩타이드 변이체 및 이를 포함하는 그람음성균에 대한 항생제
CA3184447A1 (en) * 2020-05-22 2021-11-25 Lysentech Co., Ltd. Novel polypeptide, fusion polypeptide, and antibiotic against gram-negative bacteria comprising same
KR102419028B1 (ko) * 2021-01-06 2022-07-08 주식회사 리신바이오 박테리오파지 유래 신규 재조합 엔도라이신 및 이의 용도
US11452757B2 (en) * 2021-02-25 2022-09-27 Intron Biotechnology, Inc. Antibacterial composition effective in treating gram negative bacterial infections and method for preparing the same
KR20230024845A (ko) * 2021-08-09 2023-02-21 주식회사 레고켐 바이오사이언스 신규 항생제 및 이의 용도
WO2023034646A2 (en) * 2021-09-03 2023-03-09 Aanika Biosciences, Inc. Lysecd7 variants and methods of using the same
US11548917B1 (en) * 2021-11-24 2023-01-10 Intron Biotechnology, Inc. Antibacterial composition effective in treating gram negative bacterial infections and method for preparing the same
WO2023139605A1 (en) * 2022-01-20 2023-07-27 Techinvention Lifecare Pvt. Ltd. Lysin polypeptides and compositions thereof against urinary tract infection caused by drug-resistant gram- negative bacteria

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040076590A1 (en) 2002-07-08 2004-04-22 Wilkins Joe S. Antibacterial toothpaste and mouthwash formulations
CN101094427B (zh) 2006-06-23 2010-05-12 华为技术有限公司 全网信令消息采集系统及方法
HUE031136T2 (en) 2007-07-26 2017-07-28 Revance Therapeutics Inc Antimicrobial peptide and preparations
BRPI1015192A2 (pt) * 2009-06-26 2019-09-17 Katholieke Univ Leuven K U Leuven R&D agentes antimicrobianos
AU2010288559B8 (en) 2009-08-24 2015-08-13 Katholieke Universiteit Leuven, K.U. Leuven R&D New endolysin OBPgpLYS
CN102021161A (zh) 2009-09-22 2011-04-20 昆山博青生物科技有限公司 一种制备肺炎链球菌噬菌体裂解酶的方法
PT3443970T (pt) * 2010-09-17 2020-10-09 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Fagos antibacterianos, péptidos fágicos e métodos de utilização dos mesmos
EP2468856A1 (en) 2010-12-23 2012-06-27 Lysando Aktiengesellschaft Antimicrobial Agents
WO2012114833A1 (ja) * 2011-02-22 2012-08-30 Dic株式会社 水性ウレタン樹脂組成物及びそれを用いて得られるフィルム及び光学フィルム
CN108578685A (zh) 2011-04-21 2018-09-28 洛克菲勒大学 用于革兰氏阳性菌检测和治疗的链球菌属细菌噬菌体溶素
EP2993181A1 (en) 2011-04-27 2016-03-09 Lysando AG New antimicrobial agents
WO2013044055A2 (en) 2011-09-23 2013-03-28 Quantum Engineered Products, Inc. Low profile jack
AU2013259512B2 (en) * 2012-05-09 2018-01-25 Contrafect Corporation Bacteriophage lysin and antibiotic combinations against gram positive bacteria
EP2679677A1 (en) 2012-06-29 2014-01-01 Lysando Aktiengesellschaft Composition for use in Mycobacteria therapy
US9139626B2 (en) * 2012-09-13 2015-09-22 The Mitre Corporation Mitrecin A polypeptide with antimicrobial activity
EP2951548A2 (en) 2013-01-29 2015-12-09 Wideco Sweden AB System for monitoring pipeline leakage, pipeline element provided with the system, and method for mounting the monitoring system onto a pipeline
CN105101796B (zh) * 2013-02-06 2017-06-06 中央研究院 衍生自b型肝炎病毒核蛋白精氨酸密集区的抗菌胜肽
WO2015070912A1 (en) 2013-11-14 2015-05-21 Lysando Ag Modified el188 endolysin sequence
WO2015070911A1 (en) 2013-11-14 2015-05-21 Lysando Ag Modified kz144 endolysin sequence
RU2728682C2 (ru) * 2015-09-17 2020-07-31 Контрафект Корпорейшн Применение лизина для восстановления/увеличения антибактериальной активности антибиотиков в присутствии легочного сурфактанта, который ингибирует указанные антибиотики

Also Published As

Publication number Publication date
WO2017049233A3 (en) 2017-06-01
ES2934714T3 (es) 2023-02-24
RU2018107249A3 (es) 2020-01-10
US20190290672A1 (en) 2019-09-26
CA2998507A1 (en) 2017-03-23
RU2018107245A3 (es) 2019-10-18
US20220362352A1 (en) 2022-11-17
AU2016324307A1 (en) 2018-03-22
CN108348574A (zh) 2018-07-31
MX2018003100A (es) 2019-04-15
IL258123B (en) 2021-03-25
RU2728682C2 (ru) 2020-07-31
EP3349780B1 (en) 2022-11-09
EP4115897A1 (en) 2023-01-11
RU2724545C2 (ru) 2020-06-23
JP2018534247A (ja) 2018-11-22
RU2018107249A (ru) 2019-10-17
CA2998484A1 (en) 2017-03-23
HK1256628A1 (zh) 2019-09-27
EP4151228A3 (en) 2023-06-14
CN108135971A (zh) 2018-06-08
WO2017049233A2 (en) 2017-03-23
AU2016324298B2 (en) 2022-09-01
US11413334B2 (en) 2022-08-16
MX2022006525A (es) 2022-07-11
US10744189B2 (en) 2020-08-18
BR112018005318A2 (pt) 2018-12-11
KR20180052754A (ko) 2018-05-18
CN116077630A (zh) 2023-05-09
AU2016324307B2 (en) 2021-10-21
AU2022252850A1 (en) 2022-11-17
EP3349781A2 (en) 2018-07-25
IL258123A (en) 2018-05-31
US20190070269A1 (en) 2019-03-07
IL258122A (en) 2018-05-31
IL258122B (en) 2020-08-31
EP4151228A2 (en) 2023-03-22
JP7029805B2 (ja) 2022-03-04
WO2017049242A2 (en) 2017-03-23
US20200376096A1 (en) 2020-12-03
CN108348574B (zh) 2022-11-01
AU2016324298A1 (en) 2018-03-22
ZA201801315B (en) 2018-11-28
BR112018005316A2 (pt) 2018-12-11
EP3349780A2 (en) 2018-07-25
US11357833B2 (en) 2022-06-14
US20230050560A1 (en) 2023-02-16
KR20180064417A (ko) 2018-06-14
JP2022065075A (ja) 2022-04-26
RU2018107245A (ru) 2019-10-18
JP2018527378A (ja) 2018-09-20
WO2017049242A3 (en) 2017-06-01
ZA201801316B (en) 2018-11-28

Similar Documents

Publication Publication Date Title
MX2022006525A (es) Activo de polipeptidos de lisina contra bacterias gram-negativas.
EP4282489A3 (en) Treatment of clostridium difficile infection
PH12016501577A1 (en) Monobactam organic compounds for the treatment of bacterial infections
WO2016179440A3 (en) Antimicrobial therapy
MX2016015218A (es) Antibioticos macrociclicos de amplio espectro.
MX2019007613A (es) Terapia de combinacion con compuestos ?-lactamicos sustituidos con amidina e inhibidores de ?-lactamasa para infecciones con cepas bacterianas resistentes a antibioticos.
WO2017083431A3 (en) Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections
WO2018208987A3 (en) Antibacterial compounds
WO2012003474A3 (en) Compositions and methods related to protein a (spa) variants
WO2015003816A3 (en) Cystobactamides
PH12019500360A1 (en) Antibiotic compounds
MX2020006191A (es) Bacteriocinas terapeuticas.
MX2018006190A (es) Antibioticos de amplio espectro macrociclico.
WO2015200783A3 (en) Acinetobacter lysins
MX2017009094A (es) Derivado de polimixina y usos del mismo.
WO2017218922A3 (en) Compositions and methods for the treatment of bacterial infections
ZA202002093B (en) Antibacterial compounds
MX2018006199A (es) Antibioticos de amplio espectro macrociclico.
WO2017075188A3 (en) Methods of using anti-alpha toxin antibody
MX2019015007A (es) Composiciones inmunogénicas que comprenden los polipéptidos derivados de la leucocidina de staphylococcus aureus luka y lukb.
PH12018500358A1 (en) Compounds for use in an antibacterial applications
PH12019501904A1 (en) Macrocyclic broad spectrum antibiotics
PH12016501532A1 (en) Antibacterial combinations comprising polymyxin
MX2017007969A (es) Bacterias de acido lactico y su uso para el tratamiento de mastitis.
EP3856213A4 (en) METHOD OF TREATMENT OF INFECTIONS USING BACTERIA